EC approves AMGEVITATM (biosimilar adalimumab) for treatment of inflammatory disease
Amgen announced the EC has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab1) in all available indications. AMGEVITA is authorized for treatment of certain inflammatory diseases in adults. The EC also approved AMGEVITA for treatment of certain pediatric inflammatory diseases. March 23, 2017